VistaPath, a Cambridge, MA-based leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, announced that it secured $4 million in seed funding.
The round was led by Moxxie Ventures, with participation from NextGen Venture Partners and First Star Ventures.
With this latest round, VistaPath will further advance its mission to modernize pathology labs, delivering faster, more accurate diagnoses that lead to optimal patient care.
Company: Vistapath Biosystems, Inc.
Round: Seed Round
Funding Month: June 2022
Lead Investors: Moxxie Ventures
Additional Investors: NextGen Venture Partners and First Star Ventures
Company Website: https://www.vistapathbio.com/
Software Category: AI-based, data-driven pathology processing
About the Company: VistaPath is modernizing pathology labs using computer vision and artificial intelligence. They provide clients with significant quality, workflow, and strategic benefits with the overall goal of delivering improved results for pathologists, clinicians, and patients. The Sentinel is the company's first product, Sentinel is a first-of-its-kind pathology processing platform designed to seamlessly deliver a range of solutions for critical lab processes.